Phase I study of S-222611 in patients with advanced EGFR- and/or HER2-expressing solid tumours
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2015
At a glance
- Drugs S 222611 (Primary)
- Indications Advanced breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 12 Dec 2015 Results (n=76) presented at the 38th Annual San Antonio Breast Cancer Symposium.
- 29 Oct 2015 Status changed from active, no longer recruiting to completed as results of both escalation and expansion phase are published.
- 02 Jun 2015 Results (Expansion; n=76) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History